Statins for hemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D Study.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 27181775.
- Also identified by DOI 10.1016/j.kint.2016.02.045.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The clinical benefits of statins in dialysis patients are unproven. New follow-up data from the 4D Study indicate no clear reduction in cardiovascular events among patients with type-2 diabetes. Assessing outcomes 7.4 years beyond the randomization period (20 mg atorvastatin versus placebo), no differences in a composite cardiovascular outcome were observed and no safety concerns emerged. Current Kidney Disease: Improving Global Outcomes (KDIGO) guidelines do not need updating based on these new data.
Medical subject headings
- Heptanoic Acids
- Hydroxymethylglutaryl-CoA Reductase Inhibitors